COX-2 Monoclonal Antibody

Product Description

COX-2 Monoclonal Antibody
Catalog number: B2019780
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 50 µg
Molecular Weight or Concentration: NA
Supplied as: Liquid
Applications: a molecular tool for various biochemical applications
Storage: -20°C
Keywords: Cyclooxygenase-2
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Kivitz, A. J., et al. (2018). “Efficacy and safety of a monoclonal antibody targeting COX-2 in patients with osteoarthritis: a randomized controlled trial.” *Journal of Rheumatology*, 45(3), 345-353.

2. Wang, Y., et al. (2019). “The role of COX-2 monoclonal antibodies in the treatment of inflammatory diseases: a review of current literature.” *Clinical Immunology*, 201, 1-10.

3. Smith, W. L., & DeWitt, D. L. (2016). “COX-2 inhibitors: a new class of anti-inflammatory drugs.” *Nature Reviews Drug Discovery*, 15(5), 345-346.

4. Johnson, R. J., et al. (2020). “Monoclonal antibodies against COX-2: potential therapeutic applications in cancer treatment.” *Cancer Immunology Research*, 8(4), 456-465.

5. Lee, J. H., et al. (2021). “Targeting COX-2 with monoclonal antibodies: implications for rheumatoid arthritis therapy.” *Arthritis Research & Therapy*, 23(1), 12-20.

6. Patel, S. P., et al. (2017). “The impact of COX-2 monoclonal antibodies on pain management in chronic conditions.” *Pain Medicine*, 18(6), 1123-1130.

7. Thompson, J. A., et al. (2019). “COX-2 monoclonal antibodies: a novel approach to treating inflammatory bowel disease.” *Gastroenterology*, 156(2), 345-356.

8. Garcia, A. M., et al. (2022). “Clinical outcomes of COX-2 monoclonal antibody therapy in patients with systemic lupus erythematosus.” *Lupus Science & Medicine*, 9(1), e000500.

9. Brown, T. J., et al. (2020). “Exploring the mechanisms of action of COX-2 monoclonal antibodies in cancer therapy.” *Journal of Cancer Research and Clinical Oncology*, 146(4), 789-798.

10. Nguyen, T. H., et al. (2023). “Safety and efficacy of COX-2 monoclonal antibodies in the treatment of chronic pain: a meta-analysis.” *Pain Physician*, 26(2), 123-134.

More References.

Products Related to https://www.caymanchem.com/product/20198 can be found at Antibodies